Page last updated: 2024-11-07

5-fluoro-3-pyridinecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

5-fluoro-3-pyridinecarboxylic acid, also known as nicotinic acid, is a heterocyclic compound that has been investigated for its potential therapeutic properties. It has been studied as a precursor for the synthesis of other bioactive molecules, particularly in the field of medicinal chemistry. The compound exhibits a variety of biological activities, including anti-inflammatory and antimicrobial properties. Its importance lies in its potential to serve as a building block for the development of new drugs for the treatment of various diseases. Research on 5-fluoro-3-pyridinecarboxylic acid is ongoing to explore its full therapeutic potential and to understand its precise mechanisms of action.'

Cross-References

ID SourceID
PubMed CID120232
CHEMBL ID397783
SCHEMBL ID430582
MeSH IDM0080803

Synonyms (35)

Synonym
AC-1806
5-fluoronicotinic acid ,
nicotinic acid, 5-fluoro-
3-pyridinecarboxylic acid, 5-fluoro-
5-fluoro-3-pyridinecarboxylic acid
CHEMBL397783 ,
AKOS005137907
402-66-4
FT-0660654
bdbm50216521
5-fluoropyridine-3-carboxylic acid
A6737
3-fluoro-5-carboxypyridine
5-fluoronicotinicacid
F0738
9c94xts5cx ,
unii-9c94xts5cx
5-fluoro-nicotinic acid
FT-0600683
3-fluoro-5-pyridinecarboxylic acid
AM20051156
PB23226
SCHEMBL430582
SY005275
mfcd01318537
PS-9027
J-517558
F1905-7160
DTXSID60193200
CS-W016443
STL553784
BCP24542
BBL100212
EN300-98110
Z1192357288
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-aspartate oxidaseHomo sapiens (human)IC50 (µMol)10,000.00000.00400.39370.8550AID1247843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 2Homo sapiens (human)EC50 (µMol)5.30000.00871.20176.3096AID308653
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
negative regulation of lipid catabolic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of adiponectin secretionHydroxycarboxylic acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 2Homo sapiens (human)
inseminationD-aspartate oxidaseHomo sapiens (human)
grooming behaviorD-aspartate oxidaseHomo sapiens (human)
regulation of cell communicationD-aspartate oxidaseHomo sapiens (human)
D-amino acid catabolic processD-aspartate oxidaseHomo sapiens (human)
hormone metabolic processD-aspartate oxidaseHomo sapiens (human)
nervous system processD-aspartate oxidaseHomo sapiens (human)
aspartate catabolic processD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
nicotinic acid receptor activityHydroxycarboxylic acid receptor 2Homo sapiens (human)
protein bindingD-aspartate oxidaseHomo sapiens (human)
D-aspartate oxidase activityD-aspartate oxidaseHomo sapiens (human)
D-glutamate oxidase activityD-aspartate oxidaseHomo sapiens (human)
FAD bindingD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomal matrixD-aspartate oxidaseHomo sapiens (human)
cytosolD-aspartate oxidaseHomo sapiens (human)
cytoplasmD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1247843Inhibition of human recombinant DDO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID308653Agonist activity at human cloned GPR109a receptor by forskolin-stimulated cAMP production test2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Agonist lead identification for the high affinity niacin receptor GPR109a.
AID1247844Inhibition of human recombinant DAO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]